tiprankstipranks
Gain Therapeutics to present at MJFF’s Annual Parkinson’s Disease Conference
PremiumThe FlyGain Therapeutics to present at MJFF’s Annual Parkinson’s Disease Conference
2M ago
Gain Therapeutics Excels in Neurodegenerative Drug Trials
Premium
Company Announcements
Gain Therapeutics Excels in Neurodegenerative Drug Trials
2M ago
Gain Therapeutics presents preclinical data on GT-02287
Premium
The Fly
Gain Therapeutics presents preclinical data on GT-02287
2M ago
Gain Therapeutics reports Q2 EPS (42c), consensus (20c)
PremiumThe FlyGain Therapeutics reports Q2 EPS (42c), consensus (20c)
4M ago
Gain Therapeutics Advances Parkinson’s Treatment in Phase 1
Premium
Company Announcements
Gain Therapeutics Advances Parkinson’s Treatment in Phase 1
5M ago
Gain Therapeutics completes dosing in MAD Phase 1 study of GT-02287
Premium
The Fly
Gain Therapeutics completes dosing in MAD Phase 1 study of GT-02287
5M ago
Gain Therapeutics Launches Public Offering and Warrants Deal
PremiumCompany AnnouncementsGain Therapeutics Launches Public Offering and Warrants Deal
5M ago
Gain Therapeutics 7.12M share Spot Secondary priced at $1.35
Premium
The Fly
Gain Therapeutics 7.12M share Spot Secondary priced at $1.35
5M ago
Gain Therapeutics announces common stock, warrants offering, no amount given
Premium
The Fly
Gain Therapeutics announces common stock, warrants offering, no amount given
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100